Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles - PubMed (original) (raw)
doi: 10.1016/j.ccr.2007.11.005.
Claudia Scholl, Ross L Levine, Marc Loriaux, Titus J Boggon, Olivier A Bernard, Roland Berger, Hartmut Döhner, Konstanze Döhner, Benjamin L Ebert, Sewit Teckie, Todd R Golub, Jingrui Jiang, Marcus M Schittenhelm, Benjamin H Lee, James D Griffin, Richard M Stone, Michael C Heinrich, Michael W Deininger, Brian J Druker, D Gary Gilliland
Affiliations
- PMID: 18068628
- DOI: 10.1016/j.ccr.2007.11.005
Free article
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Fröhling et al. Cancer Cell. 2007 Dec.
Free article
Abstract
Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 mutations and experimentally tested the consequences of each candidate leukemogenic allele. This approach identified gain-of-function mutations that activated downstream signaling and conferred sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including mutations in the catalytic domain. These findings support the concept that acquired mutations in cancer may not contribute to malignant transformation and underscore the importance of functional studies to distinguish "driver" mutations underlying tumorigenesis from biologically neutral "passenger" alterations.
Similar articles
- Backseat drivers take the wheel.
Futreal PA. Futreal PA. Cancer Cell. 2007 Dec;12(6):493-4. doi: 10.1016/j.ccr.2007.11.020. Cancer Cell. 2007. PMID: 18068625 Free PMC article. - Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Opatz S, Polzer H, Herold T, Konstandin NP, Ksienzyk B, Zellmeier E, Vosberg S, Graf A, Krebs S, Blum H, Hopfner KP, Kakadia PM, Schneider S, Dufour A, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA. Opatz S, et al. Blood. 2013 Sep 5;122(10):1761-9. doi: 10.1182/blood-2013-01-476473. Epub 2013 Jul 22. Blood. 2013. PMID: 23878140 Clinical Trial. - Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, Hopfner KP, Hiddemann W, Spiekermann K. Reindl C, et al. Blood. 2006 May 1;107(9):3700-7. doi: 10.1182/blood-2005-06-2596. Epub 2006 Jan 12. Blood. 2006. PMID: 16410449 - FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H, Kawashima N, Ishikawa Y. Kiyoi H, et al. Cancer Sci. 2020 Feb;111(2):312-322. doi: 10.1111/cas.14274. Epub 2019 Dec 30. Cancer Sci. 2020. PMID: 31821677 Free PMC article. Review. - Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, Dun MD. Staudt D, et al. Int J Mol Sci. 2018 Oct 16;19(10):3198. doi: 10.3390/ijms19103198. Int J Mol Sci. 2018. PMID: 30332834 Free PMC article. Review.
Cited by
- Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy.
Zhao L, Chen H, Lan F, Hao J, Zhang W, Li Y, Yin Y, Huang M, Wu X. Zhao L, et al. Int J Mol Sci. 2024 Sep 4;25(17):9581. doi: 10.3390/ijms25179581. Int J Mol Sci. 2024. PMID: 39273530 Free PMC article. - Precision medicine in AML: overcoming resistance.
Urrutia S, Takahashi K. Urrutia S, et al. Int J Hematol. 2024 Oct;120(4):439-454. doi: 10.1007/s12185-024-03827-8. Epub 2024 Aug 1. Int J Hematol. 2024. PMID: 39085680 Review. - The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus.
Bergeron J, Capo-Chichi JM, Tsui H, Mahe E, Berardi P, Minden MD, Brandwein JM, Schuh AC. Bergeron J, et al. Curr Oncol. 2023 Dec 12;30(12):10410-10436. doi: 10.3390/curroncol30120759. Curr Oncol. 2023. PMID: 38132393 Free PMC article. - FLT3 targeting in the modern era: from clonal selection to combination therapies.
Kennedy VE, Smith CC. Kennedy VE, et al. Int J Hematol. 2023 Dec 19. doi: 10.1007/s12185-023-03681-0. Online ahead of print. Int J Hematol. 2023. PMID: 38112995 Review. - Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A, Richer C, Ouimet M, Fuchs C, Langlois S, Khater F, Caron M, Beaulieu P, St-Onge P, Bataille AR, Sinnett D. Gutierrez-Camino A, et al. Br J Cancer. 2024 Feb;130(2):317-326. doi: 10.1038/s41416-023-02511-8. Epub 2023 Dec 4. Br J Cancer. 2024. PMID: 38049555 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA66996/CA/NCI NIH HHS/United States
- CA113434/CA/NCI NIH HHS/United States
- CA105423/CA/NCI NIH HHS/United States
- T32 CA009172/CA/NCI NIH HHS/United States
- HL082677/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous